SDC3 and Alzheimer disease: To evaluate SDC3 expression as a novel biomarker for AD, we first established and compared the clinical and laboratory profiles of two well-defined patient groups: individuals with clinically confirmed AD (AD group, n = 22) and a cognitively unimpaired cohort without AD (non-AD group, n = 20).